ESMO Congress 2021: highlights from the EORTC gastrointestinal
tract cancer group's perspective

J 2022

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

KOESSLER, T., M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. COLLIENNE et. al.

Basic information

Original name

ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective

Authors

KOESSLER, T. (guarantor), M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. COLLIENNE, M. P. LUTZ, C. NEUZILLET, Radka OBERMANNOVÁ (203 Czech Republic, belonging to the institution), M. PEETERS, F. SCLAFANI, E. SMYTH, J. W. VALLE, A. D. WAGNER, L. WYRWICZ, E. FONTANA and M. MOEHLER

Edition

ESMO OPEN, AMSTERDAM, ELSEVIER, 2022, 2059-7029

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 7.300

RIV identification code

RIV/00216224:14110/22:00128331

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1016/j.esmoop.2022.100392

UT WoS

000819921700001

Keywords in English

oesophagus cancer; stomach cancer; pancreatic cancer; neuroendocrine tumours; colorectal cancer

Abstract

V originále

There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.

Citovat

KOESSLER, T., M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. COLLIENNE, M. P. LUTZ, C. NEUZILLET, Radka OBERMANNOVÁ, M. PEETERS, F. SCLAFANI, E. SMYTH, J. W. VALLE, A. D. WAGNER, L. WYRWICZ, E. FONTANA and M. MOEHLER. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective. ESMO OPEN. AMSTERDAM: ELSEVIER, 2022, vol. 7, No 2, p. 1-8. ISSN 2059-7029. Available from: https://dx.doi.org/10.1016/j.esmoop.2022.100392.

@article{2250084,
   author = {Koessler, T. and Alsina, M. and Arnold, D. and BenandAharon, I. and Collienne, M. and Lutz, M. P. and Neuzillet, C. and Obermannová, Radka and Peeters, M. and Sclafani, F. and Smyth, E. and Valle, J. W. and Wagner, A. D. and Wyrwicz, L. and Fontana, E. and Moehler, M.},
   article_location = {AMSTERDAM},
   article_number = {2},
   doi = {http://dx.doi.org/10.1016/j.esmoop.2022.100392},
   keywords = {oesophagus cancer; stomach cancer; pancreatic cancer; neuroendocrine tumours; colorectal cancer},
   language = {eng},
   issn = {2059-7029},
   journal = {ESMO OPEN},
   title = {ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective},
   url = {https://www.sciencedirect.com/science/article/pii/S2059702922000126?via%3Dihub},
   volume = {7},
   year = {2022}
}

TY  - JOUR
ID  - 2250084
AU  - Koessler, T. - Alsina, M. - Arnold, D. - Ben-Aharon, I. - Collienne, M. - Lutz, M. P. - Neuzillet, C. - Obermannová, Radka - Peeters, M. - Sclafani, F. - Smyth, E. - Valle, J. W. - Wagner, A. D. - Wyrwicz, L. - Fontana, E. - Moehler, M.
PY  - 2022
TI  - ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective
JF  - ESMO OPEN
VL  - 7
IS  - 2
SP  - 1-8
EP  - 1-8
PB  - ELSEVIER
SN  - 20597029
KW  - oesophagus cancer
KW  - stomach cancer
KW  - pancreatic cancer
KW  - neuroendocrine tumours
KW  - colorectal cancer
UR  - https://www.sciencedirect.com/science/article/pii/S2059702922000126?via%3Dihub
N2  - There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.
ER  -

KOESSLER, T., M. ALSINA, D. ARNOLD, I. BEN-AHARON, M. COLLIENNE, M. P. LUTZ, C. NEUZILLET, Radka OBERMANNOVÁ, M. PEETERS, F. SCLAFANI, E. SMYTH, J. W. VALLE, A. D. WAGNER, L. WYRWICZ, E. FONTANA and M. MOEHLER. ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer group's perspective. \textit{ESMO OPEN}. AMSTERDAM: ELSEVIER, 2022, vol.~7, No~2, p.~1-8. ISSN~2059-7029. Available from: https://dx.doi.org/10.1016/j.esmoop.2022.100392.

Detailed Information on Publication Record